Article originally appeared in The Motley Fool. by George Budwell Cannabis, in many ways, became a legitimate investing arena in 2018. Even so, the nascent cannabis space still has a long way to go before many of its most serious risk factors are a thing of the past. Fortunately, there are a handful of companies operating in less controversial...
Article originally appeared in The Motley Fool. Following the crowd may give one a sense of security, but it’s in finding stocks no one else is looking at that the real opportunity lies. If a stock is flying under Wall Street’s radar, there’s good chance an issue is being mispriced by the market. We asked three...
Originally appeared in the Market Exclusive written by ME Staff. As the United States waits for president Trump to sign the 2018 Farm Bill before next year, cannabis operator Marimed Inc (OTCMKTS:MRMD) has made an official announcement concerning a significant investment in hemp. The statement has hailed the passing of the Bill and its becoming law soon as this...
This article originally appeared in The Motley Fool written by Sean Williams. This has been nothing short of a transformational year for the marijuana industry. In October, Canada became the first industrialized country in the world to legalize recreational weed, opening the door to what should be billions of dollars in added annual sales once the industry has had...
2. MariMed Halfway through 2018, MariMed already ranked as the top-performing marijuana stock of all. Its winning ways continued in the second half of the year despite a marked decline over the last couple of months. MariMed is set to finish 2018 up more than 300%. The company’s revenue soared in 2018, with $8.4 million made in...
Article originally appeared in MMJ Reporter written by Chris Stewart MariMed Inc (OTCMKTS:MRMD) is all set to maintain the leadership position in the Hemp CBD sector with an imminent signing of 2018 US Farm Bill into law. President Donald Trump is expected to sign the US Farm bill into a law soon so that US citizens can enjoy the...
Originally appeared in the Boston Business Journal written by Don Seiffert. At any given time, a drug developer is at the top — and bottom — of the list of publicly traded companies in Massachusetts with the biggest stock gains or losses, given the biotech industry’s high volatility. In 2018, however, a small, Norwood-based firm in the burgeoning...
Originally appeared in Oracle Dispatch written by James Hudson We continue to view Marimed Inc (OTCMKTS:MRMD) as one of the most interesting stories in the cannabis space right now, given the stock’s combination of a genuine under-the-radar feel and its clear sector outperformance. To that end, the company just reported its Q3 financial numbers, which helped to hold it...
Originally appeared in Canton Caller written by a staff writer Investors may be interested in considering the Gross Margin score on shares of MariMed Inc. (OTCPK:MRMD). The name at present has a score of 50.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands...
Originally appeared in Investor Place written by Josh Enomoto Marimed (MRMD) Whenever you’re dealing with pot stocks, it’s difficult to filter hype from reality. While I broadly consider the sector a paradigm-shattering opportunity, whenever money is involved, hucksters quickly follow. That’s why I appreciate what Marimed(OTCMKTS:MRMD) has to offer. Primarily, I dig MRMD stock for the underlying...
